Influenza Vaccines Market Report 2020-2030
The emergence of a Universal Flu Vaccine
The influenza vaccine market is constantly thriving to improve vaccine efficiency and provide better protection each season. Is this possible? Pharma companies tackle novel approaches to vaccine technology, better administration and delivery, plus production of the vaccine. Never has this been more critical – yet never before has it offered you such opportunity for development.
Forecasts to 2030 and other analyses reveal the commercial prospects
- In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares of your main competitors.
- Original analyses – this is not available anywhere else
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
By Vaccine Type
- Quadrivalent
- Trivalent
- Hospitals
- Specialty Clinics
- Other End-Users
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1. Global Influenza Vaccines Market Segmentation
- 1.1 Why You Should Read This Report
- 1.2 What This Report Delivers
- 1.3 Key Questions Answered By This Analytical Report Include:
- 1.4 Who is This Report For?
- 1.5 Methodology
- 1.5.1 Market Evaluation & Forecasting Methodology
- 1.6 Frequently Asked Questions (FAQs)
- 1.7 Associated Visiongain Reports
- 1.8 About Visiongain
- 2 Introduction
- 2.1 What is Influenza
- 2.2 Bird Flu
- 2.2.1 The avian influenza virus causes bird flu. Birds can be infected by influenza A viruses and all of its subtypes.
- 2.3 Annual Epidemics
- 2.3.1 Every year influenza causes 3-5 million cases of severe illness
- 2.4 Social & Economic Burden
- 2.4.1 An estimated $17 billion in the US alone is spent on direct medical costs and loss of labor on adults who have contracted influenza
- 3 Influenza Vaccine by Technology
- 3.1 Egg Based Flu Vaccine
- 3.1.1 The egg-based production system is used to make almost 500 million doses of flu vaccine every year.
- 3.2 Cell-Based Flu Vaccines
- 3.2.1 FDA issued an approval for Seqirus, the sole FDA-approved cell-based flu vaccine manufacturer in the United States, to use cell-grown CVVs.
- 3.3 Recombinant Flu Vaccines
- 3.3.1 This process can produce vaccine in the shortest amount of time
- 4 Executive Summary
- 4.1 Trivalent vaccine type anticipated to hold ~US$ 3.6 billion revenue in 2020
- 4.2 Quadrivalent to witness a CAGR of over 8%
- 4.3 Asia Pacific to witness the highest CAGR of over ~6%
- 5 Global Influenza Vaccines Market Overview
- 5.1 Drivers
- 5.1.1 Growing Elderly Population: Influenza vaccinations account for 50% of the demand for elderly people over 65 years
- 5.1.2 Growing Investments in Vaccine Development: Strong impetus for vaccine manufacturers to renew and/or expand research efforts
- 5.1.3 High Prevalence of Infectious Diseases: High prevalence of diseases, such as cholera, tuberculosis, hepatitis, and malaria will ensure strong demand for associated vaccines
- 5.1.4 Rising R&D Activities: Rising prevalence of infectious diseases and the growing focus on the immunization programs are considered as the major factors that are projected to enhance the growth
- 5.1.5 Increase in Government Focus on Immunization Programs: Broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs
- 5.1.6 Paediatric Influenza Vaccines: Paediatric influenza vaccines make up the second largest share of this vaccine industry
- 5.2 Restraints
- 5.2.1 Inadequate Reimbursement Coverage: National Immunization Survey found that 79% of privately insured children had some sort of payment associated with their last immunization visit.
- 5.2.2 Longer timelines required for Vaccine Production: Vaccine development is a long, complex process, often lasting 10-15 years
- 5.3 Opportunities
- 5.3.1 Rising Demand from Emerging Economies: China and India have already implemented the influenza vaccine into their immunization programmes
- 5.4 Market Trends
- 5.4.1 Demand Driven Trends: Developing economies are increasingly looking to improve their healthcare systems
- 5.4.2 Funding Trends: Despite the trend of increasing demand and supply in the future for the influenza vaccines market, funding is another factor that will affect the growth of the market
- 5.4.3 Protecting Workforce: Influenza results in hospitalization of up to 200,000 people each year. Such healthcare costs and burden have forced the governments to recognize the severity of influenza as a serious infection
- 5.5 SWOT Analysis
- 5.5.1 Strengths
- 5.5.1.1 Ageing Population
- 5.5.1.2 Influenza Prevention is Crucial
- 5.5.1.3 Growing Emerging Economies
- 5.5.1.4 Rising Disease Awareness
- 5.5.2 Weaknesses
- 5.5.2.1 Supply Chain Costs
- 5.5.2.2 Time Constraints
- 5.5.2.3 Barriers to Entry
- 5.5.2.4 Storage and Handling of Influenza Vaccines
- 5.5.3 Opportunities
- 5.5.3.1 Strong R&D Pipeline
- 5.5.3.2 Innovations and Technological Advancements
- 5.5.3.3 Universal Flu Vaccine
- 5.5.3.4 Adult Vaccines
- 5.5.4 Threats
- 5.5.4.1 Productivity Gap
- 5.6 PEST Analysis
- 5.6.1 Political Factors
- 5.6.1.1 Influence of Governments: The economic issues are very closely linked to the political issues that could influence the influenza vaccines market
- 5.6.2 Economic Factors
- 5.6.2.1 Cost & Time: Cost is a big factor in most things, and the influenza vaccines industry is no exception
- 5.6.2.2 Emerging Economies: High needs for preventive medicine across emerging economies to boost market growth
- 5.6.3 Social Factors
- 5.6.3.1 Creating a Healthier Society: One of the biggest social factors of the influenza vaccines industry would be the obvious benefits to healthcare that they bring
- 5.6.3.2 Public Fears of Side-Effects: On the flip side of the health benefits that vaccines bring, we can see slight resistance to vaccines from some
- 5.6.4 Technological Factors
- 5.6.4.1 Advancements in Vaccine Technology: Advancements being made in the influenza vaccine development will play a part in the future of the business
- 5.7 R&D Landscape Analysis
- 5.7.1 Fluzone® QIV HD: Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.
- 5.7.2 AFLURIA® Quad (Quadrivalent Egg-based Influenza Vaccine): Afluria Quad™ is an inactivated quadrivalent influenza vaccine indicated for use in adults aged 18 years and over.
- 5.7.3 FLUCELVAX®: FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.
- 5.7.4 FLUAD®: FLUAD is approved in over 30 countries; and to date, more than 81 million FLUAD doses have been distributed worldwide.
- 5.7.5 UNI-FLU: This candidate is a nanoparticle vaccine that self-assembles during production and that displays a cross-reactive antigen for each broad influenza group
- 5.7.6 NanoFlu™
- 6 Market Comparison Developed V.S. Emerging Economies
- 6.1 Developed Economies
- 6.2 Emerging Economies
- 6.3 Influenza Vaccine Situation Across LMIC Region
- 6.3.1 Egypt: Vaccination coverage remains low in Egypt
- 6.3.2 Lebanon: Uptake of the vaccines is improving; it is still a long way to achieve full coverage of high-risk vaccines.
- 6.3.3 Saudi Arabia: There have also been several public awareness campaigns the flu vaccine is administered and funded by MoH.
- 7 Global Influenza Vaccines Market Size Forecast 2020-2030 by Vaccine Type
- 7.1 Global Influenza Vaccines Market for Quadrivalent Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.1.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.1.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.1.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.1.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Quadrivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.2 Global Influenza Vaccines Market for Trivalent Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.2.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.2.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.2.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 7.2.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Trivalent Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8 Global Influenza Vaccines Market Size Forecast 2020-2030 by End-Users
- 8.1 Global Influenza Vaccines Market for Hospitals Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.1.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.1.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.1.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.1.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Hospitals Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.2 Global Influenza Vaccines Market for Specialty clinics segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.2.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.2.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.2.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.2.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Specialty Clinics Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.3 Global Influenza Vaccines Market for Other End-Users Segment: Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.3.1 “V” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.3.2 “U” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.3.3 “W” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 8.3.4 “L” Shaped Recovery: Global Influenza Vaccines Market for Other End-Users Revenue Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 9 Regional and Leading National Influenza Vaccines Market Forecasts 2020-2030
- 9.1 Global Influenza Vaccines Market by National Market Forecast 2020-2030
- 9.1.1 "V" Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 9.1.2 "U" Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 9.1.3 "W" Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 9.1.4 "L" Shaped Recovery: Global Influenza Vaccines Market Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- 10 North America
- 10.1 North America Influenza Vaccines Market by Country Forecast 2020-2030
- 10.2 North America Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
- 10.2.1 Recovery Scenarios (V, U, W, L): North America Influenza Vaccines Market by Vaccine Type
- 10.3 North America Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
- 10.3.1 Recovery Scenarios (V, U, W, L): North America Influenza Vaccines Market by End-Users
- 10.4 U.S. Influenza Vaccines Market Forecast 2020-2030
- 10.4.1 Obama Healthcare Reform – the Benefits for Vaccine Sales
- 10.4.2 In the US Influenza Vaccines Come Equally from Manufacturers and Distributors
- 10.4.3 “V” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
- 10.4.4 “U” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
- 10.4.5 “W” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
- 10.4.6 “L” Shaped Recovery Scenario: U.S. Influenza Vaccines Market Forecast 2020-2030
- 10.5 Canada Influenza Vaccines Market Forecast 2020-2030
- 10.5.1 High Burden Among Children Population
- 10.5.2 Vaccine Products Available for Use in Canada
- 10.5.3 “V” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
- 10.5.4 “U” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
- 10.5.5 “W” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
- 10.5.6 “L” Shaped Recovery Scenario: Canada Influenza Vaccines Market Forecast 2020-2030
- 11 Europe
- 11.1 Europe Influenza Vaccines Market by Country Forecast 2020-2030
- 11.2 Europe Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
- 11.2.1 Recovery Scenarios (V, U, W, L): Europe Influenza Vaccines Market by Vaccine Type
- 11.3 Europe Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
- 11.3.1 Recovery Scenarios (V, U, W, L): Europe Influenza Vaccines Market by End-Users
- 11.4 Germany Influenza Vaccines Market Forecast 2020-2030
- 11.4.1 Economic Downturn and Ripple Effect
- 11.4.2 “V” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
- 11.4.3 “U” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
- 11.4.4 “W” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
- 11.4.5 “L” Shaped Recovery Scenario: Germany Influenza Vaccines Market Forecast 2020-2030
- 11.5 France Influenza Vaccines Market Forecast 2020-2030
- 11.5.1 Prominent Market
- 11.5.2 French Healthcare System
- 11.5.3 Doubt over Vaccine Safety Among French Population
- 11.5.4 “V” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
- 11.5.5 “U” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
- 11.5.6 “W” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
- 11.5.7 “L” Shaped Recovery Scenario: France Influenza Vaccines Market Forecast 2020-2030
- 11.6 UK Influenza Vaccines Market Forecast 2020-2030
- 11.6.1 Mature Market
- 11.6.2 “V” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
- 11.6.3 “U” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
- 11.6.4 “W” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
- 11.6.5 “L” Shaped Recovery Scenario: UK Influenza Vaccines Market Forecast 2020-2030
- 11.7 Italy Influenza Vaccines Market Forecast 2020-2030
- 11.7.1 Economic Climate
- 11.7.2 Challenges in Public Healthcare
- 11.7.3 “V” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
- 11.7.4 “U” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
- 11.7.5 “W” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
- 11.7.6 “L” Shaped Recovery Scenario: Italy Influenza Vaccines Market Forecast 2020-2030
- 11.8 Spain Influenza Vaccines Market Forecast 2020-2030
- 11.8.1 Ageing Population
- 11.8.2 Economic Challenges
- 11.8.3 “V” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
- 11.8.4 “U” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
- 11.8.5 “W” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
- 11.8.6 “L” Shaped Recovery Scenario: Spain Influenza Vaccines Market Forecast 2020-2030
- 11.9 Rest of Europe Influenza Vaccines Market Forecast 2020-2030
- 11.9.1 “V” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
- 11.9.2 “U” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
- 11.9.3 “W” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
- 11.9.4 “L” Shaped Recovery Scenario: Rest of Europe Influenza Vaccines Market Forecast 2020-2030
- 12 Asia Pacific
- 12.1 Asia Pacific Influenza Vaccines Market by Country Forecast 2020-2030
- 12.2 Asia Pacific Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
- 12.2.1 Recovery Scenarios (V, U, W, L): Asia Pacific Influenza Vaccines Market by Vaccine Type
- 12.3 Asia Pacific Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
- 12.3.1 Recovery Scenarios (V, U, W, L): Asia Pacific Influenza Vaccines Market by End-Users
- 12.4 Japan Influenza Vaccines Market Forecast 2020-2030
- 12.4.1 Challenging Market
- 12.4.2 Vaccine Gap to Offer Immense Growth Opportunities
- 12.4.3 “V” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
- 12.4.4 “U” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
- 12.4.5 “W” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
- 12.4.6 “L” Shaped Recovery Scenario: Japan Influenza Vaccines Market Forecast 2020-2030
- 12.5 China Influenza Vaccines Market Forecast 2020-2030
- 12.5.1 Growing Population
- 12.5.2 Growing National Demand
- 12.5.3 Low Confidence Towards Domestic Vaccine
- 12.5.4 Voluntarily Spending by Chinese Population
- 12.5.5 “V” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
- 12.5.6 “U” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
- 12.5.7 “W” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
- 12.5.8 “L” Shaped Recovery Scenario: China Influenza Vaccines Market Forecast 2020-2030
- 12.6 India Influenza Vaccines Market Forecast 2020-2030
- 12.6.1 Emerging Market
- 12.6.2 “V” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
- 12.6.3 “U” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
- 12.6.4 “W” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
- 12.6.5 “L” Shaped Recovery Scenario: India Influenza Vaccines Market Forecast 2020-2030
- 12.7 Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
- 12.7.1 “V” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
- 12.7.2 “U” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
- 12.7.3 “W” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
- 12.7.4 “L” Shaped Recovery Scenario: Rest of Asia Pacific Influenza Vaccines Market Forecast 2020-2030
- 13 Latin America
- 13.1 Latin America Influenza Vaccines Market by Country Forecast 2020-2030
- 13.2 Latin America Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
- 13.2.1 Recovery Scenarios (V, U, W, L): Latin America Influenza Vaccines Market by Vaccine Type
- 13.3 Latin America Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
- 13.3.1 Recovery Scenarios (V, U, W, L): Latin America Influenza Vaccines Market by End-Users
- 13.4 Brazil Influenza Vaccines Market Forecast 2020-2030
- 13.4.1 “V” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
- 13.4.2 “U” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
- 13.4.3 “W” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
- 13.4.4 “L” Shaped Recovery Scenario: Brazil Influenza Vaccines Market Forecast 2020-2030
- 13.5 Mexico Influenza Vaccines Market Forecast 2020-2030
- 13.5.1 “V” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
- 13.5.2 “U” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
- 13.5.3 “W” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
- 13.5.4 “L” Shaped Recovery Scenario: Mexico Influenza Vaccines Market Forecast 2020-2030
- 13.6 Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
- 13.6.1 “V” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
- 13.6.2 “U” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
- 13.6.3 “W” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
- 13.6.4 “L” Shaped Recovery Scenario: Rest of Latin America Influenza Vaccines Market Forecast 2020-2030
- 14 Middle East and Africa
- 14.1 Middle East and Africa Influenza Vaccines Market by Country Forecast 2020-2030
- 14.2 Middle East and Africa Influenza Vaccines Market Forecast by Vaccine Type, 2020-2030 (US$ million, AGR%)
- 14.2.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Influenza Vaccines Market by Vaccine Type
- 14.3 Middle East and Africa Influenza Vaccines Market Forecast by End-Users, 2020-2030 (US$ million, AGR%)
- 14.3.1 Recovery Scenarios (V, U, W, L): Middle East and Africa Influenza Vaccines Market by End-Users
- 14.4 GCC Influenza Vaccines Market Forecast 2020-2030
- 14.4.1 “V” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
- 14.4.2 “U” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
- 14.4.3 “W” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
- 14.4.4 “L” Shaped Recovery Scenario: GCC Influenza Vaccines Market Forecast 2020-2030
- 14.5 South Africa Influenza Vaccines Market Forecast 2020-2030
- 14.5.1 “V” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
- 14.5.2 “U” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
- 14.5.3 “W” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
- 14.5.4 “L” Shaped Recovery Scenario: South Africa Influenza Vaccines Market Forecast 2020-2030
- 14.6 Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
- 14.6.1 “V” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
- 14.6.2 “U” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
- 14.6.3 “W” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
- 14.6.4 “L” Shaped Recovery Scenario: Rest of Middle East and Africa Influenza Vaccines Market Forecast 2020-2030
- 15 Company Profiling
- 15.1 Biodiem
- 15.1.1 Biodiem: Company Snapshot
- 15.1.2 Biodiem: Company Overview
- 15.1.3 Biodiem: Financial Analysis
- 15.1.3.1 Net Revenue, 2015-2019
- 15.1.4 Biodiem: Products
- 15.1.5 Biodiem: Recent Developments
- 15.2 CSL Limited
- 15.2.1 CSL Limited: Company Snapshot
- 15.2.2 CSL Limited: Company Overview
- 15.2.3 CSL Limited: Financial Analysis
- 15.2.3.1 Net Revenue, 2015-2019
- 15.2.3.2 Gross Profit, 2015-2019
- 15.2.4 CSL Limited: Products
- 15.2.5 CSL Limited: Recent Developments
- 15.3 Emergent BioSolutions
- 15.3.1 Emergent BioSolutions: Company Snapshot
- 15.3.2 Emergent BioSolutions: Company Overview
- 15.3.3 Emergent BioSolutions: Financial Analysis
- 15.3.3.1 Net Revenue, 2015-2019
- 15.3.3.2 EBIDTA, 2015-2019
- 15.3.3.3 Gross Profit, 2015-2019
- 15.3.4 Emergent BioSolutions: Products
- 15.3.5 Emergent BioSolutions: Recent Developments
- 15.4 AstraZeneca
- 15.4.1 AstraZeneca: Company Snapshot
- 15.4.2 AstraZeneca: Company Overview
- 15.4.3 AstraZeneca: Financial Analysis
- 15.4.3.1 Net Revenue, 2015-2019
- 15.4.3.2 EBIDTA, 2015-2019
- 15.4.3.3 Gross Profit, 2015-2019
- 15.5 Merck & Co., Inc.
- 15.5.1 Merck & Co., Inc.: Company Snapshot
- 15.5.2 Merck & Co., Inc.: Company Overview
- 15.5.3 Merck & Co., Inc.: Financial Analysis
- 15.5.3.1 Net Revenue, 2015-2019
- 15.5.3.2 EBIDTA, 2015-2019
- 15.5.3.3 Gross Profit, 2015-2019
- 15.5.4 Merck & Co., Inc.: Recent Developments
- 15.6 Sanofi
- 15.6.1 Sanofi: Company Snapshot
- 15.6.2 Sanofi: Company Overview
- 15.6.3 Sanofi: Financial Analysis
- 15.6.3.1 Net Revenue, 2015-2019
- 15.6.3.2 EBIDTA, 2015-2019
- 15.6.3.3 Gross Profit, 2015-2019
- 15.6.4 Sanofi: Products
- 15.6.5 Sanofi: Recent Developments
- 15.7 F. Hoffmann-La Roche Ltd.
- 15.7.1 F. Hoffmann-La Roche Ltd.: Company Snapshot
- 15.7.2 F. Hoffmann-La Roche Ltd.: Company Overview
- 15.7.3 F. Hoffmann-La Roche Ltd.: Financial Analysis
- 15.7.3.1 Net Revenue, 2015-2019
- 15.7.3.2 EBIDTA, 2015-2019
- 15.7.3.3 Gross Profit, 2015-2019
- 15.7.4 F. Hoffmann-La Roche Ltd.: Recent Developments
- 15.8 Sinovac Biotech Ltd.
- 15.8.1 Sinovac Biotech Ltd.: Company Snapshot
- 15.8.2 Sinovac Biotech Ltd.: Company Overview
- 15.8.3 Sinovac Biotech Ltd.: Financial Analysis
- 15.8.3.1 Net Revenue, 2015-2019
- 15.8.3.2 EBIDTA, 2015-2019
- 15.8.3.3 Gross Profit, 2015-2019
- 15.8.4 Sinovac Biotech Ltd.: Recent Developments
- 15.9 Mitsubishi Tanabe Pharma Corporation
- 15.9.1 Mitsubishi Tanabe Pharma Corporation: Company Snapshot
- 15.9.2 Mitsubishi Tanabe Pharma Corporation: Company Overview
- 15.9.3 Mitsubishi Tanabe Pharma Corporation: Financial Analysis
- 15.9.3.1 Net Revenue, 2016-2018
- 15.9.4 Mitsubishi Tanabe Pharma Corporation: Recent Developments
- 15.10 Takeda Pharmaceutical Company Limited
- 15.10.1 Takeda Pharmaceutical Company Limited: Company Snapshot
- 15.10.2 Takeda Pharmaceutical Company Limited: Company Overview
- 15.10.3 Takeda Pharmaceutical Company Limited: Financial Analysis
- 15.10.3.1 Net Revenue, 2015-2019
- 15.10.3.2 EBIDTA, 2015-2019
- 15.10.3.3 Gross Profit, 2015-2019
- 16 Conclusion & Recommendations
- 16.1 Concluding Remarks
- 16.2 Prevention of Influenza by Use of Flu Shots Rises in Importance
- 16.3 Emergence of a Universal Flu Vaccine
- 16.4 Unique & Complex Market
- 16.5 Unmet Needs & Required Innovations
- List of Tables
- Table 1 Global Influenza Vaccines Market Snapshot, 2020 & 2030 (US$ million, CAGR %)
- Table 2 Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 3 "V" Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 4 "U" Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 5 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 6 "L" Shaped Recovery: Global Influenza Vaccines Market Forecast for Quadrivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 7 Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 8 "V" Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 9 "U" Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 10 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 11 "L" Shaped Recovery: Global Influenza Vaccines Market Forecast for Trivalent Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 12 Global Influenza Vaccines Market by End-Users Forecast, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 13 Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 14 "V" Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 15 "U" Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 16 “W” Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
- Table 17 "L" Shaped Recovery: Global Influenza Vaccines Market Forecast for Hospitals Segment, 2020-2030 (US$ Mn, AGR%, CAGR%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook